gemigliptin/dapagliflozin/metformin
AssetAlso Zemiglo, Forxiga
Fixed-dose combination of DPP-4 inhibitor, SGLT2 inhibitor, and biguanide for glycemic control.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- AMPK signalling
- 5
- Indications
- 388
- Trials
- 1
- Developer
Indications
5Type 2 diabetes
Phase 3, Unknown, NCT04255238, clinicaltrials.gov, 7 Oct 2026
Fasting
Phase 1, Completed, NCT07396844, clinicaltrials.gov, 7 Oct 2026
Fasting condition
Phase 1, Completed, NCT07399470, clinicaltrials.gov, 7 Oct 2026
2 more
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials388
- Evidence for its targets4
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.